While the new mRNA vaccines from Moderna and Pfizer-BioNTech have dominated the COVID-19 vaccine story, there is another type ...

Some people are making it their mission to get Novavax, rather than Pfizer or Moderna, for their COVID booster.

In the most recent trading session, Novavax (NVAX) closed at $12.80, indicating a -0.85% shift from the previous trading day.

Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

Novavax Inc. closed $11.06 below its 52-week high ($23.86), which the company achieved on June 6th.

On Monday, Novavax Inc (NVAX) stock saw a decline, ending the day at $12.8 which represents a decrease of $-0.11 or -0.85% from the prior close of $12.91. The stock opened at $13.01 and touched a low ...

With the approval of Moderna's updated COVID-19 vaccine, doctors are hoping the shots will be available soon and Albertans ...

The U.S. Food and Drug Administration on Friday granted emergency use authorization for an updated version of Novavax's COVID shot. The updated vaccine is authorized for use in individuals 12 ...

Health Canada has approved an updated Novavax COVID-19 vaccine to protect against the variants of the virus currently circulating. The move comes just after the agency approved Moderna's updated mRNA ...

The Food and Drug Administration (FDA) has authorized the emergency use of the Novavax COVID-19 Vaccine, Adjuvanted.

For many, Novavax is #1 – the one and only COVID vaccine they would consider. This enthusiasm for Novavax isn’t new. As far back as 2022, news reports described a kind of Novavax fan club – a term ...

Shares of Novavax Inc. NVAX slid 2.86% to $12.56 Wednesday, on what proved to be an all-around dismal trading session for the ...